Stay updated on Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Sign up to get notified when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.

Latest updates to the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded Illinois locations under the Locations section. Revision updated to v3.3.3.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe Publications section now states that entries are automatically filled from PubMed, and a revision tag v3.3.2 was added. The previous PubMed-origin description and the older revision tag v3.2.0 were removed.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page no longer displays the government funding lapse notice regarding updates and operating status. Core study content, eligibility criteria, and results information remain unchanged.SummaryDifference0.4%

- Check61 days agoChange DetectedNo significant additions or deletions detected in the core study information (title, condition, interventions, outcomes, eligibility, or enrollment). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check90 days agoChange DetectedThe page now includes an operating-status notice and a version update to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference2%

- Check97 days agoChange DetectedRemoved several disease/classification terms (neoplasms and carcinoma-related entries) and added a version update to v3.1.0.SummaryDifference0.5%

Stay in the know with updates to Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Guadecitabine & Pembrolizumab in Recurrent Gynecologic Cancer Clinical Trial page.